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Abstract
Introduction: To assess the rate of thyroid cancer and mortality rate in a cohort of patients who received RAI131 treatment for hyperthy-
roidism and to report the index cases’ characteristics and management 
Material and methods: A cohort of 264 patients who received RAI131 treatment for different causes of thyrotoxicosis were followed up 
over a period of 18 years (1996–2014) by physical exam, radiological evaluation and serial thyroid function tests.
Results: During the follow up period, three cases of thyroid cancer were identified. The prevalence of thyroid cancer was 1.136% of cases 
who received RAI131. The relative risk was 378.79 (95% CI: 76.8 < RR < 1868.23). The P value was < 0.0000004 and the SMR is 1.99/1000.
Conclusions: The prevalence of thyroid cancer was 1.136% in the cohort of patients treated with RAI131. Despite the fact that no direct 
cause-effect relationship between RAI and thyroid cancer could be established, these cases highlights the importance of life-long surveil-
lance of patients who receive RAI131. (Endokrynol Pol 2017; 68 (5): 561–566)
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Streszczenie
Wstęp: Badanie przeprowadzono w celu oceny częstości występowania raka tarczycy i odsetka zgonów w kohorcie chorych poddanych 
terapii RAI131 z powodu nadczynności tarczycy oraz przedstawienia charakterystyki tych chorych i stosowanego u nich leczenia. 
Materiał i metody: U kohorty 264 chorych poddanych terapii RAI131 z uwagi na tyreotoksykozę o różnej etiologii przez ponad 18 lat 
(1996–2014) prowadzono obserwację obejmującą badanie przedmiotowe, ocenę radiologiczną i serię badań czynności tarczycy.
Wyniki: W okresie obserwacji wykryto 3 przypadki raka tarczycy. Częstość występowania raka tarczycy w grupie chorych poddanych 
terapii RAI131 wynosiła 1,136%. Ryzyko względne wynosiło 378,79 (95% CI: 76,8 < RR < 1868,23). Wartości p i SMR wynosiły odpowiednio 
< 0,0000004 i 1,99/1000.
Wnioski: Częstość występowania raka tarczycy w kohorcie chorych poddanych terapii RAI131 wynosiła 1,136%. Mimo że nie wykazano 
bezpośredniego związku przyczynowo-skutkowego między RAI a rakiem tarczycy, opisane przypadki zwracają uwagę na znaczenie 
bezterminowej obserwacji chorych poddanych terapii RAI131. (Endokrynol Pol 2017; 68 (5): 561–566)
Słowa kluczowe: wole guzkowe toksyczne, rak tarczycy, jod radioaktywny
Introduction
Thyroid cancer is showing an increase in its detection 
rate globally, which is mainly explained by the detection 
of histopathological micropapillary subtype [1]. Thyroid 
cancer is the commonest endocrine malignancy with 
1–1.5% of newly diagnosed cases each year in the USA [2]. 
The worldwide relative frequency of occurrence of thy-
roid cancer is between 0.5 and 10 per 100,000 population [3] 
with a 2–3 fold increase in female preponderance [4]. 
The incidence of thyroid cancer in females is 3.3% ver-
sus 1.3% in males [5].
The prognosis for thyroid cancer is good, and the 
mortality rate remains stable over 30 years at 0.5 cases 
per 100,000 persons, despite increased incidence of new 
cases annually [6].
The incidence of thyroid cancer in thyrotoxic pa-
tients treated with radioactive iodine is higher than in 
the general population, with an increased relative risk 
of cancer that is proportional to the doses of radioac-
tive iodine administered [7]. This incidence of thyroid 
cancer peaks at the age of 50–59 years and in those older 
than 70 years of age [7].
The overall cancer mortality was not increased in 
two large American and British studies that followed 
large cohorts of thyrotoxic patients receiving RAI131, 
except for thyroid cancer [8] and small bowel cancer [9]. 
Both studies showed that the increase in thyroid cancer 
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incidence and deaths were small but that close and 
continuous attention should be paid to such patients. 
These observations, however, were not supported by 
the group of 35,000 patients followed up by Holm L-E 
et al. who did not find a proof that RAI131 is carcinogenic 
in humans [10].
According to the Middle East Cancer Consortium 
(MECC), which includes Jordan, Israel, Egypt, Cy-
prus, Palestinian Authority and Turkey, thyroid cancer 
patients revealed age standardised incidence rates 
(ASR) of 3/100,000 in Jordan in 2005 [11] (4.5/100,000 
for females and 2.7/100,000 for males [5]). The expected 
death rate for the general population in Jordan is 
3.69/100,000 [12].
In this study we identified and will discuss cases of 
thyroid cancer among a cohort of Jordanian patients 
with hyperthyroidism, who received radioactive iodine 
between 1996 and 2014, we calculate the rate of thyroid 
cancer and SMR, and discuss the association of thyroid 
cancer with RAI131.
Material and methods
Longitudinal study of 264 hyperthyroid consecutive 
patients who received RAI131 since 1996 and were 
followed-up till 2014.
Graves’ disease was diagnosed in 198 patients, 
toxic multinodular goitre in 47 and toxic nodule in 19 
patients.
Inclusion criteria included all patients who received 
RAI131 for different causes of thyrotoxicosis because of 
failure of medical treatment, patients unfit or refused 
surgery , if rapid restoration of thyroid function was 
needed, or due to the patient’s own preference.
Exclusion criteria included previous personal his-
tory of thyroid cancer, family history of thyroid cancer, 
and/or history of multiple endocrine neoplasia (MEN).
The cohort was followed-up by physical examina-
tion and serial blood testing for thyroid function test 
(TFT) every 3–6 months until full restoration of their 
clinical status to a euthyroid state and normalisation 
of TFT and/or they became clinically biochemically 
hypothyroid. TFT was then performed twice yearly 
for life. TSH was adjusted accordingly to be kept in 
the lower quartile of the reference range. FNA biopsy 
was performed in patients who noticed an increase in 
nodular size, the appearance of new nodules and/or 
lymph nodes, or the appearance of new goitres. 
Statistics
Descriptive statistics for prevalence and rates, mean 
and standard deviation (SD) for dosage, odd ratio (OR), 
relative risk (RR), and 95% confidence interval (CI) were 
calculated using Epi Info version 6 and Fisher’s exact 
test. Standard Mortality Rate per 1000 was measured by 
calculating observed mortality over expected mortality 
in the general population [12]. 
Results
A total of 264 (91 males) with a mean age(± SD) of 
43.3 ± 14.05 years received 278 doses of RAI131 with 
a mean dose of 15.98 ± 2.5 mCi and were followed-up 
for a period of 18 years (1996 to 2014) at the Endocrine 
Clinic at King Hussein Medical Centre, Amman-Jordan.
During the follow-up period, three cases of thyroid 
cancer were observed. The mean duration from RAI131 
treatment until diagnosis of cancer was 8.3 ± 5.1 years. 
The prevalence of thyroid cancer in this cohort was 
1.136%. The Relative risk was 378.79 (95% CI: 76.80 
< RR < 1868.23). P value < 0.0000004 and odds ratio: 
383.13 (95% CI: 61.7–2379.1).
The standard mortality rate (SMR) using the ex-
pected mortality rate in Jordan of 3.8/1000 is 1.99/1000 
patients receiving radioiodine treatment.
Case 1
A 75-year-old female patient, non-smoker, hyper-
tensive, on α-methyldopa 250 mg twice daily, was 
admitted in November 1992 to King Hussein Medical 
Centre with rapid atrial fibrillation and was found to 
have hyperthyroidism due to toxic multinodular goitre. 
FT3 was 5.2 ng/dL (normal range: 1.2–3.6), FT4 was 
2.9 ng/dL (0.8–1.9), and TSH was 0.006 uiU/mL (0.4–4.0). 
She denied family history for thyroid cancer or other 
malignancies (Table I).
Thyroid ultrasound was in keeping with multinodu-
lar goitre with no lymph node enlargement. Thyroid 
isotope scan revealed enlargement of the gland (left > 
right) with multiple areas of decreased tracer uptake. 
Two-dimensional echocardiography showed GII-III 
mitral regurgitation with biatrial enlargement. 
She was started on carbimazole 30 mg/day, pro-
pranolol 40 mg t.i.d., digoxin 0.25 mg/day, and warfarin 
5 mg/day. Her thyroid status remained active despite 
carbimazole dose adjustment according to thyroid 
function test. On 15th June 1998 she was given a dose 
of 25 mCi radioactive iodine. After which she became 
clinically and biochemically euthyroid but remained 
in atrial fibrillation.
She was lost from follow up for eight years. In May 
2006 she presented with increasing neck swelling, 
hoarseness of voice, shortness of breath at rest, and 
dysphagia for liquids and solid food. Physical examina-
tion revealed controlled AF and a large multinodular 
goitre, hard in consistency with enlarged cervical lymph 
nodes (Fig. 1A). She had dilated upper chest and neck 
veins and Pemberton’s sign was positive. Neurological 
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examination revealed left lower motor neuron VII 
nerve palsy. Laboratory investigations are summarised 
in Table I.
Indirect laryngoscopy demonstrated vocal cords 
that were slightly mobile. There was pooling of saliva 
and swelling of retrocricoid area causing obstruction to 
the inlet of the oesophagus. Neck, chest, abdomen and 
pelvic CT-scan showed a large heterogeneous partially 
enhanced ill-defined mass lesion with central necrosis 
in the left side of the neck extendeing from the level of 
hyoid bone down the retrosternal area and medially 
reaching the right side of the cricoid cartilage (Fig. 1B). 
The mass lesion showed calcified areas encasing the 
trachea and the carotid artery with infiltration of the 
trapezius muscle and causing a mass effect pushing the 
midline structures to the right side. Multiple variable 
sized lung nodules were seen in both lungs with right-
sided pleural effusion (Fig. 1C).
Thyroid fine needle aspiration revealed a malig-
nant process (medullary versus anaplastic carcinoma) 
(Figure 2A). Hematoxylin and eosin stain confirms the 
presence of nests of spindle-shaped to polygonal cells 
of medullary carcinoma (Figure 2B). She was treated 
conservatively with correction of hypocalcaemia but 
her obstructive symptoms were more pronounced, so 
an emergency surgery attempting to relieve obstruction 
was done. Intra-operative findings included a large thy-
roid tumour with areas of necrosis with skin and sub-
cutaneous metastatic deposits. Debulking surgery was 
attempted, but unfortunately her post-operative course 
was eventful and she succumbed postoperatively. Fami-
ly refused postmortem autopsy. The histopathological 
Figure 1A. Large multinodular goitre with enlarged cervical lymph nodes; B. Neck CT-scan showing a large, heterogeneous, partially 
enhanced, ill-defined mass lesion with central necrosis in the left side of the neck extended from the level of the hyoid bone down the 
retrosternal area and medially reaching the right side of the cricoid cartilage; C. Chest and abdomen CT-scan shows multiple variable 
sized lung nodules in both lung fields and right-sided pleural effusion
Rycina 1A. Duże wole guzkowe z powiększonymi węzłami chłonnymi szyjnym; B. W obrazie TK szyi widoczna duża, niejednorodna, 
częściowo wzmacniająca się, słabo ograniczona zmiana z martwicą w części centralnej, znajdująca się po lewej stronie szyi i rozciągająca 
się od kości gnykowej sięgając w dół do okolicy zamostkowej, a w kierunku przyśrodkowym — do chrząstki pierścieniowatej; C. Obraz 
TK klatki piersiowej i jamy brzusznej z widocznymi licznymi guzkami o różnej wielkości w obrębie obu pól płucnych oraz prawostronny 
wysięk w jamie opłucnej
Table I. Laboratory features of the three cases
Tabela I. Parametry laboratoryjne w trzech przypadkach 
raka tarczycy
Case 1 Case 2 Case 3
WBC  
(4.5–10.5 × 103)
107 × 103 9.500 × 103 8.900 × 103
PCV 42.3% 46.7% 44.1%
Platelets  
(150–450 × 103)
301 × 103 265 × 103 257 × 103
BUN  
(10–28 mg/dL)
15 18 22
Serum creatinine  
(0.5–1.5 mg/dL)
1.30 1.10 1.25
Serum calcium  
(7.8–10.2 mg/dL)
7.8 8.9 9.3
Serum Phosphorous  
(3–4.5 mg/dL)
2.9 3.4 3.5
Serum
ALP (50–160 U/L
886 155 133
Serum albumin  
(35–45 g/dL)
46 41 37
Serum uric acid  
(4–6.5 mg/dL)
12.3 5.5 6.0
PTH  
(15–64 pg/mL)
58 39 32
TSH [µu/mL] 4.47 3.34 2.9
Serum calcitonin pg/mL 11.3
24-hr urine collection for 
metanephrines (< 1 mg)
0.6
Duration from RAI131 until 
development of cancer 
[years]
7 4 14
1A 1B 1C
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examination confirmed MTC with anaplastic changes 
and positive calcitonin stain (Fig. 2C).
Case 2 (see Table I)
A 65-year-old female patient, with a known case of 
bronchial asthma and diagnosed with toxic multi-
nodular goitre in 2002. Due to early failure of medical 
therapy, she received 15 mCi RAI131 in 2003 and became 
euthyroid within six months. In April 2007 she present-
ed with neck discomfort and sensation of suffocation. 
Physical examination revealed a hard thyroid nodule. 
Neck ultrasound showed a 2.5 x 3.0 cm heterogeneous 
thyroid nodule with spots of calcifications within the 
left thyroid lobe. Other smaller, homogeneous nodules 
< 1.3 cm, were found in both thyroid lobes Thyroid 
FNA biopsy revealed papillary thyroid cancer (PTC). 
She underwent total thyroidectomy, and the frozen 
section and histopathology confirmed the diagnosis of 
PTC with no capsular invasion (Fig. 3). Post-operative 
whole body I131 scan was negative. She did not receive 
radioactive iodine ablation after surgery. She is under 
regular follow-up with serial serum thyroglobulin 
levels that are < 0.1 ng/dL and no evidence of thyroid 
remnant tissue, or cervical lymphadenopathy on regu-
lar clinical and sonographic examination of the thyroid 
bed and neck. A whole body I131 scan was done in 2012 
and it was negative. She is maintained on replacement 
suppressive therapy with levothyroxine 200 µg/day. 
Case 3 (see Table I)
A 72-year-old male patient, ex-smoker, diagnosed with 
GD in 1996. He was treated with RAI131, developed hypo-
thyroidism one year later, and was given levothyroxine 
100 µg daily. He was lost to follow-up at the endocrine 
clinic, but he remained under regular follow-up by 
a cardiologist for hypertension and ischaemic cardio-
myopathy. In 2010, he was noticed to have lateral neck 
swelling. Neck US revealed a small hyperechoic nodule 
on the left side and another smaller one on the right 
side with multiple cervical LNs, the largest measuring 
3.5 × 3 cm. The patient was referred to an endocrine 
clinic in December 2010 for further evaluation. Cervical 
LN biopsy under local anaesthesia revealed a meta-
static papillary thyroid carcinoma. He was scheduled 
for high-risk surgery after thorough multi-disciplinary 
consultations in January 2011, but he had a decom-
pensated congestive cardiac failure during this period 
and succumbed just before surgery because of new 
cardiac insult.
Discussion
The prevalence of thyroid nodules reaches up to 50% in 
late adulthood and represents a reservoir of potential 
malignancy to be investigated [13]. The majority of thy-
roid cancers (> 80%) are discovered in nodules less than 
2 cm in the largest diameter. This high percentage is due 
to increased detection of thyroid cancers by increased 
surveillance and use of more sensitive diagnostic proce-
dures [14]. The presence of thyroid nodule in a patient 
with Graves’ disease has a malignancy rate of 16.9%, 
which is higher than in the general population [15]. Ex-
posure to ionising radiation is a recognised precipitating 
factor for thyroid cancer [16]. Thyroid gland is highly 
susceptible to ionising radiation because of its position 
in the body and its ability to concentrate iodine [16]. 
The thyroid gland is amenable to the carcinogenic effect 
of radiation, and the risk of thyroid cancer decreases 
with increasing age at exposure with small risk above 
the age of 20 years [17].
Thyroid cancers after treatment with small doses of 
I131 for thyrotoxicosis are rare. Staffurth et al. reported 
a case of follicular thyroid cancer 15 years after a small 
dose of radioactive iodine (4 mCi) for Graves’ disease [18].
Figure 2A. Thyroid fine-needle aspiration revealed a malignant process (medullary versus anaplastic carcinoma); B. Haematoxylin 
and eosin stain showing nests of spindle-shaped to polygonal cells of medullary carcinoma; C. Immunohistochemistry stain shows 
a positive cytoplasmic staining for calcitonin
Rycina 2A. Biopsja cienkoigłowa tarczycy ujawniła proces nowotworowy (rak rdzeniasty versus rak anaplastyczny tarczycy); 
B. W preparacie barwionym hematoksyliną–eozyną widoczne gniazda komórek wrzecionowatych i wielokątnych raka rdzeniastego; 
C. W preparacie barwionym metodą immunohistochemiczną widoczne dodatnie cytoplazmatyczne wybarwienia kalcytoniny
2A 2B 2C
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RAI131 stimulates an increment in thyroid anti-
bodies like TSH receptor stimulating antibodies [19] 
that play a significant role in thyroid carcinogenesis 
and angiogenesis [20]. Those antibodies can result in 
stimulation of thyroid tumour cell growth by activating 
endothelial cell growth factor [21]. The occurrence of 
thyroid cancer increased significantly in children who 
were exposed to ionising radiation 10 years after the 
Chernobyl accident [22], especially the occurrence of 
papillary thyroid cancer [23] .The commonest molecular 
lesion in these tumours are a rearrangement of the RET 
receptor tyrosine kinase proto-oncogene [23]. Ogawa 
et al. showed that treatment with radioactive iodine 
(RAI131) deactivates the tumour suppressor gene that 
is commonly found in anaplastic thyroid cancer rather 
than differentiated thyroid cancer [24]. There are also 
some cytomorphological changes in thyroid follicular 
epithelium caused by radioactive iodine treatment, as 
reported by Stugis [25]. Radioactive iodine treatment 
plays a significant role in induction of cellular atypia 
with progressive metaplastic changes in patients with 
Graves’ disease. This phenomenon is actually promi-
nent in those who remain hyperthyroid after treatment 
with radioactive iodine [26].
Anaplastic thyroid cancer in hyperthyroid patients 
after an interval of time post radioactive iodine therapy 
was reported in only three cases, who were females and 
had received multiple doses of RAI131. This cancer was 
elicited 12–20 years after RAI131 [26–28]. 
The Cooperative Thyrotoxicosis Therapy Follow-up 
Study concluded that thyroid cancer after radioactive 
iodine ablation developed in those people receiving lower 
rather than higher doses of RAI131 therapy [29]. The report 
of MTC post RAI131 for TMNG that developed anaplastic 
changes in patients who received a single dose of 25 mCi of 
RAI131 represents a unique association and has never been 
reported. Despite the fact that this report of a case series 
showed an increase in the relative risk of thyroid cancer 
and SMR in patients receiving radioactive iodine treatment 
for different causes of thyrotoxicosis, it should not exclude 
3A
3D
3B
3C
Figure 3 (A–D). Showing the classic features of papillary thyroid carcinoma with multifocal lesions, papillae, grooves and clear nuclear 
features 
Rycina 3 (A–D). Widoczne klasyczne cechy raka brodawkowego tarczycy z wieloogniskowymi zmianami, strukturami brodawkowatymi, 
rowkami oraz jasnymi jądrami komórkowymi
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I131 as an important modality of treatment. This series of 
cases highlights the importance of lifelong surveillance and 
monitoring for any structural changes in thyroid tissue to 
allow early detection of potentially curable cancer. 
In conclusion, the prevalence of thyroid cancer post 
RAI131 is 1.136% in this cohort that received RAI131 and was 
followed-up for > 15 years. Radioactive iodine I131 is still 
a very effective therapy for hyperthyroidism, and the spo-
radic discovery of thyroid malignancy should not preclude 
the use of it. The development of MTC after radioactive 
iodine I131 was not reported previously. Unfortunately the 
patient did not live long enough for genetic studies to be 
done. These cases also highlight the importance of life-
long follow-up of patients treated with radioactive iodine 
to avoid such an association with probable grave outcome.
References
1. Pacini F, Castagna MG, Brilli L, et al. ESMO Guidelines Working Group. 
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treat-
ment and follow-up. Ann Oncol. 2012; 23 Suppl 7: vii110–vii119, doi: 
10.1093/annonc/mds230, indexed in Pubmed: 22997443.
2. Curado MP, Edwards B, Shin HR. Cancer Incidence in Five Continents, 
vol. 9 of IARC Scientific Publications, No. IARC, Lyon, France 2007.
3. Marjani A, Kabir MJ. Incidence of thyroid cancer in Golestan Province 
of Iran: Some initial observations. Pak J Med Sci. 2008; 24(6): 887–90.
4. Brown RL, de Souza JA, Cohen EEw. Thyroid cancer: burden of illness 
and management of disease. J Cancer. 2011; 2: 193–199, doi: 10.7150/
jca.2.193, indexed in Pubmed: 21509149.
5. Parkin DM, Whelan SL, Ferlay J, et al. eds. Cancer incidence in five continents, 
volume VIII. IARC Scientific Publication No. 155. Lyon (France): International 
Agency for Research on Cancer. ; 2002, indexed in Pubmed: 12812229.
6. Davies L, Welch HG. Increasing incidence of thyroid cancer in the 
United States, 1973-2002. JAMA. 2006; 295(18): 2164–2167, doi: 10.1001/
jama.295.18.2164, indexed in Pubmed: 16684987.
7. Metso S, Auvinen A, Huhtala H, et al. Increased cancer incidence after 
radioiodine treatment for hyperthyroidism. Cancer. 2007; 109(10): 
1972–1979, doi: 10.1002/cncr.22635.
8. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treat-
ment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy 
Follow-up Study Group. JAMA. 1998; 280(4): 347–355, doi: 10.1001/
jama.280.4.347, indexed in Pubmed: 9686552.
9. Franklyn JA, Maisonneuve P, Sheppard M, et al. Cancer incidence and 
mortality after radioiodine treatment for hyperthyroidism: a population-
based cohort study. Lancet. 1999; 353(9170): 2111–2115, doi: 10.1016/
S0140-6736(98)12295-X, indexed in Pubmed: 10382695.
10. Holm LE, Hall P, Lundell G, et al. Cancer risk after iodine-131 therapy 
for hyperthyroidism. J Natl Cancer Inst. 1991; 83(15): 1072–1077, doi: 
10.1093/jnci/83.15.1072, indexed in Pubmed: 1875414.
11. Ghazi FS, Mohammad RT, Kamal HA, et al. Epidemiology of Thyroid 
Cancer in Jordan from 1996 to 2008. Middle East Journal of Cancer 2011; 
2 (3. ; 4: 117–123.
12. www.trading economics.com/Jordan/death-rate-crude-per-1-000-peo-
ple-wb-data.html (June 2015).
13. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 
1993; 328(8): 553–559, doi: 10.1056/NEJM199302253280807, indexed in 
Pubmed: 8426623.
14. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United 
States, 1973–2002. JAMA. 2006; 295(18): 2164–2167.
15. Belfiore A, Russo D, Vigneri R, et al. Graves’ disease, thyroid nodules 
and thyroid cancer. Clin Endocrinol (Oxf). 2001; 55(6): 711–718, doi: 
10.1046/j.1365-2265.2001.01415.x, indexed in Pubmed: 11895209.
16. Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence 
of thyroid cancer: update on epidemiology and risk factors. J Cancer 
Epidemiol. 2013; 2013: 965212, doi: 10.1155/2013/965212, indexed in 
Pubmed: 23737785.
17. Holm LE. Thyroid cancer after exposure to radioactive 131I. Acta On-
col. 2006; 45(8): 1037–1040, doi: 10.1080/02841860500516600, indexed in 
Pubmed: 17118835.
18. Staffurth JS, Holl-Allen RT. Follicular carcinoma of the thyroid following 
radioactive iodine treatment for Graves’ disease. Postgraduate Medical 
Journal. 1988; 64(757): 878–880, doi: 10.1136/pgmj.64.757.878.
19. DeGroot LJ. Radioiodine and the immune system. Thyroid. 1997; 7(2): 
259–264, doi: 10.1089/thy.1997.7.259, indexed in Pubmed: 9133697.
20. Fujikawa M, Okamura K, Sato K, et al. Anaplastic transformation of 
a papillary carcinoma of the thyroid in a patient with Graves’ disease 
with varied activity of thyrotropin receptor antibodies. Thyroid. 1998; 
8(1): 53–58, doi: 10.1089/thy.1998.8.53, indexed in Pubmed: 9492154.
21. Hoffmann S, Hofbauer LC, Scharrenbach V, et al. Thyrotropin (TSH)-
induced production of vascular endothelial growth factor in thyroid 
cancer cells in vitro: evaluation of TSH signal transduction and of 
angiogenesis-stimulating growth factors. J Clin Endocrinol Metab. 2004; 
89(12): 6139–6145, doi: 10.1210/jc.2004-1260, indexed in Pubmed: 15579770.
22. Smeesters P, Frühling J, Van Bladel L, et al. [Nuclear accidents and iodine 
prophylaxis. Part 1: Risks due to irradiation of the thyroid gland]. Rev 
Med Brux. 1998; 19(6): 475–482, indexed in Pubmed: 9916494.
23. Klugbauer S, Pfeiffer P, Gassenhuber H, et al. RET rearrangements in 
radiation-induced papillary thyroid carcinomas: high prevalence of 
topoisomerase I sites at breakpoints and microhomology-mediated end 
joining in ELE1 and RET chimeric genes. Genomics. 2001; 73(2): 149–160, 
doi: 10.1006/geno.2000.6434, indexed in Pubmed: 11318605.
24. Ogawa M, Hori H, Hirayama M, et al. Anaplastic transformation from 
papillary thyroid carcinoma with increased serum CA19-9. Pediatr 
Blood Cancer. 2005; 45(1): 64–67, doi: 10.1002/pbc.20375, indexed in 
Pubmed: 15770642.
25. Sturgis CD. Radioactive iodine-associated cytomorphologic alterations 
in thyroid follicular epithelium: is recognition possible in fine-needle 
aspiration specimens? Diagn Cytopathol. 1999; 21(3): 207–210, doi: 
10.1002/(sici)1097-0339(199909)21:3<207::aid-dc13>3.0.co;2-e, indexed 
in Pubmed: 10450109.
26. Kim SH, Kim HY, Jung KY, et al. Anaplastic thyroid carcinoma follow-
ing radioactive iodine therapy for graves’ disease. Endocrinol Metab 
(Seoul). 2013; 28(1): 61–64, doi: 10.3803/EnM.2013.28.1.61, indexed in 
Pubmed: 24396653.
27. Baker H. Anaplastic thyroid cancer twelve years after radioiodine therapy. 
Cancer. 1969; 23(4): 885–890, doi: 10.1002/1097-0142(196904)23:4<885::aid-
cncr2820230425>3.0.co;2-r.
28. Gossage AA, Neal FE, Ross CM, et al. Cases of carcinoma of thyroid fol-
lowing iodine-131 therapy for hyperthyroidism. Oncology. 1984; 41(1): 
8–12, doi: 10.1159/000225782, indexed in Pubmed: 6700935.
29. Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves’ 
disease is radioiodine. J Clin Endocrinol Metab. 2007; 92(3): 797–800, 
doi: 10.1210/jc.2006-1239, indexed in Pubmed: 17341574.
